Processa Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 13
- Market Cap
- -
- Introduction
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
Processa Pharmaceuticals Doses First Patient in Phase II Trial of NGC-Cap for Metastatic Breast Cancer
• Processa Pharmaceuticals has dosed the first patient in a Phase II clinical trial of Next Generation Capecitabine (NGC-Cap) for advanced or metastatic breast cancer.
• The global, multi-center, open-label, adaptive trial will enroll 60 to 90 patients to compare two doses of NGC-Cap with FDA-approved capecitabine.
• The trial aims to assess NGC-Cap's safety and efficacy, determine optimal dosing, and explore personalized therapy potential, with an interim analysis expected in mid-2025.
• NGC-Cap combines PCS6422, a DPD enzyme inhibitor, with low-dose capecitabine to reduce side effects and enhance cancer-killing effects.
© Copyright 2025. All Rights Reserved by MedPath